Assay ID | Title | Year | Journal | Article |
AID96841 | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 200 mg/kg (treatment of 1qd schedule) dosage; Range is 14-23 | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID96549 | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by change in tumor weight at 200 mg/kg (treatment of 1qd schedule) dosage | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID153306 | Antitumor activity was determined against the ip implanted P388 leukemia in mice by percent median survival rate (treated/control) at 200 mg/kg (1 qd treatment schedule) dosage; >45.0/12.0 | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID96701 | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 300 mg/kg (1 qd treatment schedule) dosage; Range is 14-18 | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID98958 | Antitumor activity against the ip implanted L1210 leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID152682 | Antitumor activity against the ip implanted P388 leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID153000 | Antitumor activity was determined against the ip implanted P388 leukemia in mice by 45-day survivors in mice at 200 mg/kg (1 qd treatment schedule) dosage | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID97105 | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 300 mg/kg (1 qd treatment schedule) dosage | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID97224 | Antitumor activity against ip implanted L1210 leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 100-250 | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID154854 | Antitumor activity was determined against the ip implanted P388 leukemia in mice by change in tumor weight at 200 mg/kg (1 qd treatment schedule) dosage | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID152822 | Antitumor activity was determined against the ip implanted P388 leukemia in mice by range in survival days at 200 mg/kg (1 qd treatment schedule) dosage; Range is 24->45 | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID96543 | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 300 mg/kg (1 qd treatment schedule) dosage | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID97618 | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent median survival rate (treated/control) at 300 mg/kg (1 qd treatment schedule) dosage; 14.5/7.0 | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID97288 | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by 45-day survivors in mice at 200 mg/kg (treatment of 1qd schedule) dosage | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID97112 | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent increase in life span at 200 mg/kg (treatment of 1qd schedule) dosage | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID97627 | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent median survival rate (treated/control) at 200 mg/kg (treatment of 1qd schedule) dosage; 19.5/7.0 | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID153284 | Antitumor activity was determined against the ip implanted P388 leukemia in mice by percent increase in life span at 200 mg/kg (1 qd treatment schedule) dosage | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID152368 | Antitumor activity against ip implanted P388 leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 200-300 | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
AID100492 | Antitumor activity against the ic implanted L1210 lymphoid leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |